1-16 of 16
Ling Xu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 4746: PLB-001, a novel anti-dll3 ADC with topoisomerase 1 inhibitor-based linker-payload for treatment of SCLC

Free
Yingdong Lu, xin li, Ganyuan Xiao, Kia J. Puan, Ling xu, Mao Yin
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 4746.
https://doi.org/10.1158/1538-7445.AM2025-4746
Published: 21 April 2025
View articletitled, Abstract 4746: PLB-001, a novel anti-dll3 ADC with topoisomerase 1 inhibitor-based linker-payload for treatment of SCLC
Journal Articles

Abstract 7218: Preventive use of trilaciclib in Chinese patient with extensive-stage small cell lung cancer (ES-SCLC) receiving chemotherapy: A multi-center, single-arm, observational real-world study

Free
Ying Liu, Jianqiang Bi, Jianxin Chen, Meifang Chen, Xuesong Chen, Yongxing chen, Yinghua Ji, Yujie Jiang, Lu Li, Qin Liao, Sheng Lin, Jie Liu, Yi Liu, Yu Liu, Zhaoting Meng, Zhuqing Mu, Yunxiang Qi, Yanhong Shang, Ling Xu, Shufeng Xu, Lu Zheng, Jin Zhou, Ying Cheng
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 7218.
https://doi.org/10.1158/1538-7445.AM2025-7218
Published: 21 April 2025
View articletitled, Abstract 7218: Preventive use of trilaciclib in Chinese patient with extensive-stage small cell lung cancer (ES-SCLC) receiving chemotherapy: A multi-center, single-arm, observational real-world study
Journal Articles

Abstract 2945: PLB-002 is a novel Claudin 6 antibody-drug conjugate for ovarian cancer and testicular germ cell cancer

Free
Haitao Pan, Qing Zhang, Ganyuan Xiao, Guangchao Zhang, Jiaxin Li, Ling Xin, Kia J. Puan, Ling Xu, Yingdong Lu, Mao Yin
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 2945.
https://doi.org/10.1158/1538-7445.AM2025-2945
Published: 21 April 2025
View articletitled, Abstract 2945: PLB-002 is a novel Claudin 6 antibody-drug conjugate for ovarian cancer and testicular germ cell cancer
Journal Articles

Abstract PO4-05-04: Comparative effectiveness of Palbociclib plus Aromatase inhibitor versus fulvestrant alone as initial endocrine therapy for HR+/HER2- advanced breast cancer in Chinese clinical practice: a real-world study

Free
Jian Yue, Xue Wang, Jie Ju, Zixiang Yang, Tong Wei, Peng Yuan, Min Gao, Ling Xu, Yin Guan
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO4-05-04.
https://doi.org/10.1158/1538-7445.SABCS23-PO4-05-04
Published: 02 May 2024
View articletitled, Abstract PO4-05-04: Comparative effectiveness of Palbociclib plus Aromatase inhibitor versus fulvestrant alone as initial endocrine therapy for HR+/HER2- advanced breast cancer in Chinese clinical practice: a real-world study
Journal Articles

Metabolic and Nonmetabolic Functions of PSAT1 Coordinate Signaling Cascades to Confer EGFR Inhibitor Resistance and Drive Progression in Lung Adenocarcinoma

Available to Purchase
Ming-Yu Luo, Ye Zhou, Wei-Ming Gu, Cheng Wang, Ning-Xiang Shen, Jiang-Kai Dong, Hui-Min Lei, Ya-Bin Tang, Qian Liang, Jing-Hua Zou, Lu Xu, Pengfei Ma, Guanglei Zhuang, Ling Bi, Ling Xu, Liang Zhu, Hong-Zhuan Chen, Ying Shen
Journal: Cancer Research
Cancer Res (2022) 82 (19): 3516–3531.
https://doi.org/10.1158/0008-5472.CAN-21-4074
Published: 04 October 2022
View articletitled, Metabolic and Nonmetabolic Functions of PSAT1 Coordinate Signaling Cascades to Confer EGFR Inhibitor Resistance and Drive Progression in Lung Adenocarcinoma
Open the PDF for Metabolic and Nonmetabolic Functions of PSAT1 Coordinate Signaling Cascades to Confer EGFR Inhibitor Resistance and Drive Progression in Lung Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab

Free
Jeremy R. Duvall, Raghida A. Bukhalid, Naniye M. Cetinbas, Kalli C. Catcott, Kelly Lancaster, Keith W. Bentley, Suzanna Clark, Susan Clardy, Scott D. Collins, Anouk Dirksen, Elizabeth Ditty, Bingfan Du, Eugene W. Kelleher, Travis Monnell, Marina Protopopova, Caitlin Routhier, Cheri Stevenson, Elena Ter-Ovanesyan, Joshua D. Thomas, Alex Uttard, Jason Wang, Phonphimon Wongthida, Ling Xu, Annika Yau, Jeffrey Zurita, Dorin Toader, Marc Damelin, Timothy B. Lowinger
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3503.
https://doi.org/10.1158/1538-7445.AM2022-3503
Published: 15 June 2022
View articletitled, Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab
Journal Articles

Abstract 907: XMT-1660, a B7-H4-targeted Dolasynthen antibody-drug conjugate for the treatment of breast cancer

Free
Shawn P. Fessler, Jason Wang, Scott D. Collins, LiuLiang Qin, Kenneth Avocetien, Ling Xu, Ronald Eydelloth, Steven Vonderfecht, Chen-Ni Chin, Steven Bradley, Susan Clardy, Anouk Dirksen, Elizabeth Ditty, Bingfan Du, Dokyong Kim, Rebecca Mosher, Elena Ter-Ovanesyen, Kelly Slocum, Alex Uttard, Phonphimon Wongthida, Jeffrey Zurita, Dorin Toader, Marc Damelin, Timothy B. Lowinger
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 907.
https://doi.org/10.1158/1538-7445.AM2021-907
Published: 01 July 2021
View articletitled, Abstract 907: XMT-1660, a B7-H4-targeted Dolasynthen antibody-drug conjugate for the treatment of breast cancer
Journal Articles

Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity

Free
Jeremy R. Duvall, Raghida A. Bukhalid, Naniye M. Cetinbas, Kalli C. Catcott, Kelly Slocum, Kenneth Avocetien, Keith W. Bentley, Stephen Bradley, Susan Clardy, Scott D. Collins, Elizabeth Ditty, Timothy Eitas, Brian D. Jones, Eugene W. Kelleher, Winnie Lee, Travis Monnell, Rebecca Mosher, Marina Protopopova, LiuLiang Qin, Pamela Shaw, Elena Ter-Ovanesyan, Joshua D. Thomas, Phonphimon Wongthida, Ling Xu, Liping Yang, Jeffrey Zurita, Dorin Toader, Marc Damelin, Timothy B. Lowinger
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1738.
https://doi.org/10.1158/1538-7445.AM2021-1738
Published: 01 July 2021
View articletitled, Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity
Journal Articles

Abstract 2894: XMT-1592, a site-specific Dolasynthen-based NaPi2b-targeted antibody-drug conjugate for the treatment of ovarian cancer and lung adenocarcinoma

Free
Shawn Fessler, Anouk Dirksen, Scott D. Collins, Ling Xu, Winnie Lee, Jason Wang, Ron Eydelloth, Elena Ter-Ovanesyen, Jeffrey Zurita, Elizabeth Ditty, Barrett Nehilla, Susan Clardy, Susan Clardy, Tyler Carter, Kenneth Avocetien, Mark Nazzaro, Nam Le, Kalli C. Catcott, Alex Uttard, Bingfan Du, Chen-Ni Chin, Rebecca Mosher, Kelly Slocum, Liuliang Qin, David Lee, Dorin Toader, Marc Damelin, Timothy B. Lowinger
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 2894.
https://doi.org/10.1158/1538-7445.AM2020-2894
Published: 15 August 2020
View articletitled, Abstract 2894: XMT-1592, a site-specific Dolasynthen-based NaPi2b-targeted antibody-drug conjugate for the treatment of ovarian cancer and lung adenocarcinoma
Journal Articles

Abstract 6706: Systemic administration of STING agonist antibody-drug conjugates elicit potent anti-tumor immune responses with minimal induction of circulating cytokines

Free
Raghida A. Bukhalid, Jeremy R. Duvall, Naniye Malli Cetinbas, Kalli C. Catcott, Kenneth Avocetien, Keith W. Bentley, Stephen Bradley, Tyler Carter, Chen-Ni Chin, Susan Clardy, Scott D. Collins, Timothy Eitas, Brian D. Jones, Eugene W. Kelleher, Rebecca Mosher, Mark Nazzaro, Marina Protopopova, Pamela Shaw, Kelly Slocum, Elena Ter-Ovanesyan, LiuLiang Qin, Joshua D. Thomas, Ling Xu, Liping Yang, Jeffrey Zurita, Dorin Toader, Marc Damelin, Timothy B. Lowinger
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 6706.
https://doi.org/10.1158/1538-7445.AM2020-6706
Published: 15 August 2020
View articletitled, Abstract 6706: Systemic administration of STING agonist antibody-drug conjugates elicit potent anti-tumor immune responses with minimal induction of circulating cytokines
Journal Articles

Abstract 2687: Dolasynthen–a novel, homogeneous Auristatin F hydroxypropyl amide antibody-drug conjugate platform

Free
Dorin Toader, Marc Damelin, Anouk Dirksen, Shawn P. Fesler, Scott D. Collins, Barrett J. Nehilla, Jian Xu, Ling Xu, Kalli C. Cattcott, Alex Uttard, Winnie Lee, Susan Clardy, Cheri A. Stevenson, LiuLiang Qin, Patrick R. Conlon, Mariya V. Kozytska, Chen-Ni Chin, David H. Lee, Timothy B. Lowinger
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 2687.
https://doi.org/10.1158/1538-7445.AM2019-2687
Published: 01 July 2019
View articletitled, Abstract 2687: Dolasynthen–a novel, homogeneous Auristatin F hydroxypropyl amide antibody-drug conjugate platform
Journal Articles

Abstract 1665: AZ304, a novel dual BRAF inhibitor, exerts antitumor activity in colorectal cancers independent of BRAF status

Free
Rui Ma, Ling Xu, Xiaofang Che, Xiujuan Qu, Lisa Drew, Minhui Shen, Tony Cheung, Yunpeng Liu
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1665.
https://doi.org/10.1158/1538-7445.AM2018-1665
Published: 01 July 2018
View articletitled, Abstract 1665: AZ304, a novel dual BRAF inhibitor, exerts antitumor activity in colorectal cancers independent of BRAF status
Journal Articles

Abstract 754: Unique pharmacologic properties of Dolaflexin-based ADCs—a controlled bystander effect

Free
Susan M. Clardy, Alex Yurkovetskiy, Mao Yin, Dmitry Gumerov, Ling Xu, Elena Ter-Ovanesyan, Charlie Bu, Alex Johnson, Marina Protopopova, Qingxiu Zhang, Natalya Bodyak, Marc Damelin, David H. Lee, Donald Bergstrom, Timothy B. Lowinger
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 754.
https://doi.org/10.1158/1538-7445.AM2018-754
Published: 01 July 2018
View articletitled, Abstract 754: Unique pharmacologic properties of Dolaflexin-based ADCs—a controlled bystander effect
Journal Articles

Abstract 4195: β-elemene inhibits the metastasis of multidrug-resistant gastric cancer cells through the Cbl-b-EGFR-ERK/Akt signaling pathway

Free
Ruoxi Yu, Mingming Deng, Huicong Song, Dan Zou, Ling Xu, Xiujuan Qu, Yunpeng Liu, Yuee Teng, Xuejun Hu, Ye Zhang
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 4195.
https://doi.org/10.1158/1538-7445.AM2018-4195
Published: 01 July 2018
View articletitled, Abstract 4195: β-elemene inhibits the metastasis of multidrug-resistant gastric cancer cells through the Cbl-b-EGFR-ERK/Akt signaling pathway
Journal Articles

Abstract 4916: E3 ubiquitin ligase Cbl-b prevents tumor metastasis by maintaining the epithelial phenotype in multiple drug-resistant gastric and breast cancer cells

Free
Ling Xu, Xiujuan Qu, Ye Zhang, Xiaofang Che, Tianshu Guo, Ying Cai, Aodi Li, Danni Li, Ce Li, Ti Wen, Yibo Fan, Kezuo Hou, Yanju Ma, Xuejun Hu, Yunpeng Liu
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 4916.
https://doi.org/10.1158/1538-7445.AM2017-4916
Published: 01 July 2017
View articletitled, Abstract 4916: E3 ubiquitin ligase Cbl-b prevents tumor metastasis by maintaining the epithelial phenotype in multiple drug-resistant gastric and breast cancer cells
Journal Articles

Abstract 714: Cbl-b Inhibits p-gp transporter function by preventing its translocation into caveolae in multiple drug-resistant gastric and breast cancers

Free
Ye Zhang, Xiujuan Qu, Yuee Teng, Ling Xu, Jing Liu, Zhi Li, Xuejun Hu, Yunpeng Liu
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 714.
https://doi.org/10.1158/1538-7445.AM2015-714
Published: 01 August 2015
View articletitled, Abstract 714: Cbl-b Inhibits p-gp transporter function by preventing its translocation into caveolae in multiple drug-resistant gastric and breast cancers